Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
Title:
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
Author:
Mahlangu, Johnny Levy, Howard Kosinova, Marina V. Khachatryan, Heghine Korczowski, Bartosz Makhaldiani, Levani Iosava, Genadi Lee, Martin Del Greco, Frank
Appeared in:
Research and practice in thrombosis and haemostasis
Paging:
Volume 5 () nr. 6 pages p.
Year:
2021
Contents:
Publisher:
Catalyst Biosciences. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).